Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective Phase II Trial of Molecular Profiling to Guide Neoadjuvant Therapy for Resectable and Borderline Resectable Adenocarcinoma of the Pancreas

NCT01726582 is registered in ClinicalTrials.gov with Medical College of Wisconsin as lead sponsor.

NCT NCT01726582
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01726582 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective Phase II Trial of Molecular Profiling to Guide Neoadjuvant Therapy for Resectable and Borderline Resectable Adenocarcinoma of the Pancreas
Lead sponsor
Medical College of Wisconsin
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2011
Completion date
April 11, 2022
Enrollment
229 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic adenocarcinoma